Financhill
Sell
30

AKRO Quote, Financials, Valuation and Earnings

Last price:
$44.84
Seasonality move :
-5.43%
Day range:
$43.87 - $45.39
52-week range:
$17.86 - $58.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.76x
Volume:
866.8K
Avg. volume:
968.3K
1-year change:
62.96%
Market cap:
$3.6B
Revenue:
--
EPS (TTM):
-$3.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AKRO
Akero Therapeutics
-- -$1.12 -- -16.23% $77.64
ALLK
Allakos
-- -$0.18 -- -62.96% $0.35
BIIB
Biogen
$2.4B $3.36 -1.89% 33.96% $201.18
CYTK
Cytokinetics
$14.3M -$1.17 270.16% -2.37% $79.10
ETNB
89bio
-- -$0.76 -- -10.19% $27.55
SAGE
Sage Therapeutics
$14.4M -$1.36 79.76% -43.33% $8.05
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AKRO
Akero Therapeutics
$44.88 $77.64 $3.6B -- $0.00 0% --
ALLK
Allakos
$0.25 $0.35 $22.9M -- $0.00 0% --
BIIB
Biogen
$143.54 $201.18 $21B 12.83x $0.00 0% 2.17x
CYTK
Cytokinetics
$44.91 $79.10 $5.3B -- $0.00 0% 271.64x
ETNB
89bio
$8.70 $27.55 $1.3B -- $0.00 0% --
SAGE
Sage Therapeutics
$8.02 $8.05 $493.1M -- $0.00 0% 11.82x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AKRO
Akero Therapeutics
-- 3.401 -- --
ALLK
Allakos
-- -4.402 -- --
BIIB
Biogen
27.36% 0.257 28.25% 0.77x
CYTK
Cytokinetics
125.95% 0.821 11.82% 6.08x
ETNB
89bio
-- 2.587 -- --
SAGE
Sage Therapeutics
-- 0.494 -- 7.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AKRO
Akero Therapeutics
-- -$78M -- -- -- -$67.1M
ALLK
Allakos
-- -$24.7M -- -- -- -$12.5M
BIIB
Biogen
$1.9B $450.6M 7.33% 10.33% 14.32% $694.6M
CYTK
Cytokinetics
-$76.7M -$139M -123.83% -- -752.8% -$66.9M
ETNB
89bio
-- -$122M -- -- -- -$121.6M
SAGE
Sage Therapeutics
$11.3M -$80.3M -63.59% -63.59% -626.87% -$66.6M

Akero Therapeutics vs. Competitors

  • Which has Higher Returns AKRO or ALLK?

    Allakos has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat Allakos's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    ALLK
    Allakos
    -- -- --
  • What do Analysts Say About AKRO or ALLK?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Allakos has an analysts' consensus of $0.35 which suggests that it could grow by 37.85%. Given that Akero Therapeutics has higher upside potential than Allakos, analysts believe Akero Therapeutics is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    ALLK
    Allakos
    0 7 0
  • Is AKRO or ALLK More Risky?

    Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Allakos has a beta of 0.719, suggesting its less volatile than the S&P 500 by 28.106%.

  • Which is a Better Dividend Stock AKRO or ALLK?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allakos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Allakos pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or ALLK?

    Akero Therapeutics quarterly revenues are --, which are smaller than Allakos quarterly revenues of --. Akero Therapeutics's net income of -$70M is lower than Allakos's net income of $376K. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Allakos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for Allakos. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    ALLK
    Allakos
    -- -- -- $376K
  • Which has Higher Returns AKRO or BIIB?

    Biogen has a net margin of -- compared to Akero Therapeutics's net margin of 10.87%. Akero Therapeutics's return on equity of -- beat Biogen's return on equity of 10.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    BIIB
    Biogen
    76.23% $1.83 $23B
  • What do Analysts Say About AKRO or BIIB?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Biogen has an analysts' consensus of $201.18 which suggests that it could grow by 40.16%. Given that Akero Therapeutics has higher upside potential than Biogen, analysts believe Akero Therapeutics is more attractive than Biogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    BIIB
    Biogen
    13 17 0
  • Is AKRO or BIIB More Risky?

    Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Biogen has a beta of 0.012, suggesting its less volatile than the S&P 500 by 98.773%.

  • Which is a Better Dividend Stock AKRO or BIIB?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or BIIB?

    Akero Therapeutics quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Akero Therapeutics's net income of -$70M is lower than Biogen's net income of $266.7M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 12.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 2.17x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    BIIB
    Biogen
    2.17x 12.83x $2.5B $266.7M
  • Which has Higher Returns AKRO or CYTK?

    Cytokinetics has a net margin of -- compared to Akero Therapeutics's net margin of -886.28%. Akero Therapeutics's return on equity of -- beat Cytokinetics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    CYTK
    Cytokinetics
    -453.13% -$1.26 $521.7M
  • What do Analysts Say About AKRO or CYTK?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Cytokinetics has an analysts' consensus of $79.10 which suggests that it could grow by 76.13%. Given that Cytokinetics has higher upside potential than Akero Therapeutics, analysts believe Cytokinetics is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    CYTK
    Cytokinetics
    10 3 0
  • Is AKRO or CYTK More Risky?

    Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.949, suggesting its less volatile than the S&P 500 by 5.057%.

  • Which is a Better Dividend Stock AKRO or CYTK?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or CYTK?

    Akero Therapeutics quarterly revenues are --, which are smaller than Cytokinetics quarterly revenues of $16.9M. Akero Therapeutics's net income of -$70M is higher than Cytokinetics's net income of -$150M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 271.64x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    CYTK
    Cytokinetics
    271.64x -- $16.9M -$150M
  • Which has Higher Returns AKRO or ETNB?

    89bio has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat 89bio's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    ETNB
    89bio
    -- -$1.02 --
  • What do Analysts Say About AKRO or ETNB?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand 89bio has an analysts' consensus of $27.55 which suggests that it could grow by 216.61%. Given that 89bio has higher upside potential than Akero Therapeutics, analysts believe 89bio is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    ETNB
    89bio
    8 2 0
  • Is AKRO or ETNB More Risky?

    Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison 89bio has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.566%.

  • Which is a Better Dividend Stock AKRO or ETNB?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 89bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. 89bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or ETNB?

    Akero Therapeutics quarterly revenues are --, which are smaller than 89bio quarterly revenues of --. Akero Therapeutics's net income of -$70M is higher than 89bio's net income of -$118.4M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while 89bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for 89bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    ETNB
    89bio
    -- -- -- -$118.4M
  • Which has Higher Returns AKRO or SAGE?

    Sage Therapeutics has a net margin of -- compared to Akero Therapeutics's net margin of -747.33%. Akero Therapeutics's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$0.99 --
    SAGE
    Sage Therapeutics
    88.38% -$1.56 $465.1M
  • What do Analysts Say About AKRO or SAGE?

    Akero Therapeutics has a consensus price target of $77.64, signalling upside risk potential of 72.99%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could grow by 0.33%. Given that Akero Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Akero Therapeutics is more attractive than Sage Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    9 0 0
    SAGE
    Sage Therapeutics
    0 15 0
  • Is AKRO or SAGE More Risky?

    Akero Therapeutics has a beta of -0.193, which suggesting that the stock is 119.294% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

  • Which is a Better Dividend Stock AKRO or SAGE?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or SAGE?

    Akero Therapeutics quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Akero Therapeutics's net income of -$70M is higher than Sage Therapeutics's net income of -$95.8M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 11.82x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$70M
    SAGE
    Sage Therapeutics
    11.82x -- $12.8M -$95.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
48
SMTC alert for Mar 18

Semtech [SMTC] is down 0.49% over the past day.

Buy
67
PLPC alert for Mar 18

Preformed Line Products [PLPC] is up 3.8% over the past day.

Buy
58
NUTX alert for Mar 18

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock